The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients.
dc.contributor.author | Backen, Alison C | |
dc.contributor.author | Renehan, Andrew G | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Berzuini, C | |
dc.contributor.author | Zhou, C | |
dc.contributor.author | Oza, A | |
dc.contributor.author | Bannoo, S | |
dc.contributor.author | Scherer, S | |
dc.contributor.author | Banks, R | |
dc.contributor.author | Dive, Caroline | |
dc.contributor.author | Jayson, Gordon C | |
dc.date.accessioned | 2014-07-08T13:56:52Z | |
dc.date.available | 2014-07-08T13:56:52Z | |
dc.date.issued | 2014-06-19 | |
dc.identifier.citation | The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients. 2014: Clin. Cancer Res. | en |
dc.identifier.issn | 1078-0432 | |
dc.identifier.pmid | 24947924 | |
dc.identifier.doi | 10.1158/1078-0432.CCR-13-3248 | |
dc.identifier.uri | http://hdl.handle.net/10541/322559 | |
dc.description.abstract | Purpose: Randomized ovarian cancer trials, including ICON7, have reported improved progression-free survival (PFS) when bevacizumab was added to conventional cytotoxic therapy. The improvement was modest prompting the search for predictive biomarkers for bevacizumab. Experimental Design: Pre-treatment training (n = 91) and validation (n = 114) blood samples were provided by ICON7 patients. Plasma concentrations of 15 angio-associated factors were determined using validated multiplex ELISAs. Results: The combined values of circulating Ang1 and Tie2 concentrations predicted improved PFS in bevacizumab-treated patients in the training set. Using median concentrations as cut-offs, high Ang1/low Tie2 values were associated with significantly improved PFS for bevacizumab-treated patients (median: 23.0 months versus 16.2, log rank test, p=0.006). High Ang1/high Tie2 values were associated with a poor outcome for bevacizumab-treated patients (median: 12.8 months versus 28.5 months, log rank test p=0.007). Ang1 and Tie2 jointly interacted with the effect of bevacizumab on PFS (pinteraction=0.003). The prognostic indices derived from the training set differentiated classes of high and low probability for progression in the validation set (p = 0.008). Conclusions: The combined values of Ang1 and Tie2 are predictive biomarkers for improved PFS in bevacizumab-treated patients with ovarian cancer. | |
dc.language | ENG | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Research | en |
dc.title | The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients. | en |
dc.type | Article | en |
dc.contributor.department | Clinical Experimental Pharmacology, Cancer Research UK Manchester Institute. | en |
dc.identifier.journal | Clinical Cancer Research | en |
refterms.dateFOA | 2020-05-01T14:07:51Z | |
html.description.abstract | Purpose: Randomized ovarian cancer trials, including ICON7, have reported improved progression-free survival (PFS) when bevacizumab was added to conventional cytotoxic therapy. The improvement was modest prompting the search for predictive biomarkers for bevacizumab. Experimental Design: Pre-treatment training (n = 91) and validation (n = 114) blood samples were provided by ICON7 patients. Plasma concentrations of 15 angio-associated factors were determined using validated multiplex ELISAs. Results: The combined values of circulating Ang1 and Tie2 concentrations predicted improved PFS in bevacizumab-treated patients in the training set. Using median concentrations as cut-offs, high Ang1/low Tie2 values were associated with significantly improved PFS for bevacizumab-treated patients (median: 23.0 months versus 16.2, log rank test, p=0.006). High Ang1/high Tie2 values were associated with a poor outcome for bevacizumab-treated patients (median: 12.8 months versus 28.5 months, log rank test p=0.007). Ang1 and Tie2 jointly interacted with the effect of bevacizumab on PFS (pinteraction=0.003). The prognostic indices derived from the training set differentiated classes of high and low probability for progression in the validation set (p = 0.008). Conclusions: The combined values of Ang1 and Tie2 are predictive biomarkers for improved PFS in bevacizumab-treated patients with ovarian cancer. |